1. FMC faces a class action lawsuit for alleged securities fraud activities. 2. Company's Q4 2024 results missed estimates by $90 million. 3. FMC anticipates flat revenue in 2025 due to lower inventory demand. 4. Stock fell 33.5% after disappointing earnings report and inventory concerns.
The class action lawsuit and missed revenue targets signal serious operational issues. Past instances like Valeant Pharmaceuticals saw similarly drastic stock declines after fraud allegations.
The lawsuit and recent financial results are crucial to potential investor perception and stock performance. This is a high-impact event that directly affects FMC's financial integrity.
Short-term stock price will likely continue to be impacted by the lawsuit and ongoing revenue struggles. Similar patterns have been observed in stocks facing immediate legal challenges.
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FMC Corporation ("FMC" or the "Company") (NYSE:FMC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether FMC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until April 14, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired FMC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
Click here for information about joining the class action
On February 4, 2025, FMC reported its financial results for the fourth quarter of 2024, missing consensus revenue estimates by $90 million and revealing that "growth was below [the Company's] expectations as [it] learned during the quarter that customers in many countries sought to hold significantly less inventory than they have historically." FMC also provided a Full Year 2025 outlook, disclosing that it expects revenue to remain essentially flat due to "weaker demand in the channel as customers in many countries prioritize holding lower-than-historical levels of inventory." In an earnings call held the same day, the Company disclosed that it "need[s] to significantly lower FMC inventory in the channel much beyond what we were expecting."
On this news, FMC's stock price fell $18.12 per share, or 33.5%, to close at $35.92 per share on February 5, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP